← Back

ClearOne Inc

ClearOne, Inc. does not have significant operations. Previously, the company was engaged in the design, development, and marketing of professional audio conferencing, microphone, and video collaboration solutions. ClearOne, Inc. was incorporated in 1983 and is headquartered in Salt Lake City, Utah.

Price · split & dividend adjusted
News & notes moving CLRO
Biotech & Genomic Medicine▲

ClearOne, NeOnc, Iovance, and Ensysce Advance Key Healthcare Catalysts

ClearOne, NeOnc Technologies, Iovance Biotherapeutics, and Ensysce Biosciences each reported significant clinical, regulatory, or financial developments. ClearOne moved closer to completing its acquisition of Cortigent, a neurotechnology subsidiary of Vivani Medical, after majority shareholder First Finance Ltd., which controls approximately 61.3% of voting power, approved the transaction and the issuance of 12.5 million shares. NeOnc Technologies is approaching topline Phase 2a data from its fully enrolled NEO100-01 study and has expanded internationally with a second IND authorization from Abu Dhabi for recurrent high-grade gliomas. Iovance Biotherapeutics reported record second-quarter 2026 revenue of approximately $99.3 million, a 66% year-over-year increase driven by its FDA-approved TIL therapy Amtagvi, and is reviewing its 2026 revenue guidance of $350 million to $370 million. Ensysce Biosciences acquired privately held Cy Biopharma, adding the clinical-stage neuroplastogenic therapy CY200 for Complex Regional Pain Syndrome Type 1, and secured financing that could total up to $77 million, including $17.1 million in cash and a $21.5 million private placement led by Ally Bridge Group.
IOVA ▲CLRO ▲ENSC ▲NTHI ▲
Biotech & Genomic Medicine ▲
GlobeNewswire·20dRead more ▾
Brain-Computer Interface

Vivani to merge subsidiary Cortigent with ClearOne in Nasdaq listing deal

Vivani Medical has entered into a definitive merger agreement under which its wholly owned subsidiary Cortigent will become a wholly owned subsidiary of Nasdaq-listed ClearOne, with the combined company to be renamed Cortigent Holdings and trade under the ticker CRGT. ClearOne has agreed to raise between $10,000,000 and $15,000,000 in a concurrent financing. Vivani will receive 12,500,000 shares of ClearOne common stock and is expected to own 59.4% to 67.5% of the combined company, while former ClearOne shareholders will own 12.7% to 14.4%. The transaction, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to stockholder approvals, completion of the financing, and continued Nasdaq listing. Cortigent develops brain-computer interface devices based on precision neurostimulation technology, including the Orion artificial vision system and a device to aid arm and hand recovery after stroke.
VANI ▲CLRO
Brain-Computer Interface
GlobeNewswire·55dRead more ▾
© 2026 MarketDXAsset